Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
Amneal Pharmaceuticals Q4 Adjusted EPS $0.23 Beats $0.21 Estimate, Sales $609.76M Beat $579.91M Estimate
Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.21 by 9.52 percent. This is a 35.29 percent increase over earnings of $0.17 per share from
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Amneal Pharmaceuticals Has Been Granted A CMS Permanent Product-Specific Reimbursement Q-code (Q5130) For Fylnetra Effective April 1, 2023
https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-4-2022-drugs-and-biologicals-updated-02/01/2023.pdf
Amneal Receives FDA Approval For Leuprolide Acetate Injection
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug
Amneal Pharmaceuticals Announces Commercial Launch Of ALYMSYS
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS®
